Sickle Cell Disease Management in Developing Countries

Sickle cell disease (SCD) remains a formidable healthcare challenge in developing countries, characterized by high prevalence, significant morbidity, and mortality rates. Achievements in SCD management in developing countries include increased awareness, newborn screening programs, improved access to medications like hydroxyurea, and the development of clinical guidelines. These advancements have contributed to earlier diagnosis, reduced complications, and improved overall outcomes for patients. Moreover, the emergence of online resources and telemedicine has opened new avenues for delivering care and support to SCD patients in remote or underserved areas. However, substantial challenges persist, including limited healthcare infrastructure, economic constraints, and health disparities. To address these issues effectively, recommendations have been proposed, encompassing various aspects of SCD management. These recommendations advocate for the establishment of national SCD programs, early diagnosis through newborn screening, affordable access to medications, telemedicine adoption, genetic counseling, community engagement, and continued research and data collection. Furthermore, this chapter underscores the importance of holistic and patient-centered care, emphasizing the need for multidisciplinary teams, psychological support, nutritional guidance, and educational outreach. The inclusion of patients and their families as advocates in the management process is also highlighted. In conclusion, the management of SCD in developing countries is a complex endeavor that requires a concerted effort from healthcare providers, governments, advocacy groups, and international organizations. By implementing these recommendations and fostering collaboration, it is possible to enhance the quality of life for individuals affected by SCD and reduce the burden of the disease in these regions.